Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
EyePoint Pharmaceuticals Announces First Patient Dosed In Phase 2 PAVIA Clinical Trial Of EYP-1901 For The Treatment Of Non-Proliferative Diabetic Retinopathy
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the first
Recap: EyePoint Pharmaceuticals Q2 Earnings
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
EyePoint Pharmaceuticals Q2 EPS $(0.52), Inline, Sales $11.56M Beat $10.87M Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.52) per share which met the analyst consensus estimate. This is a 23.81 percent decrease over losses of $(0.42) per share from the same period last
Earnings Preview For EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement.
Analysts estimate that EyePoint Pharmaceuticals will report an earnings per share (EPS) of $-0.52.